• Germline pathogenic variants in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms 

      Venizelos, Andreas; Sorbye, Halfdan; Elvebakken, Hege; Perren, Aurel; Lothe, Inger Marie Bowitz; Couvelard, Anne; Hjortland, Geir Olav; Sundlöv, Anna; Svensson, Johanna; Garresori, Herish; Kersten, Christian; Hofsli, Eva; Detlefsen, Sönke; Vestermark, Lene W.; Ladekarl, Morten; Tabaksblat, Elizaveta Mitkina; Knappskog, Stian (Journal article; Peer reviewed, 2023)
      High-grade gastroenteropancreatic (HG-GEP) neuroendocrine neoplasms (NENs) are highly aggressive cancers. The molecular etiology of these tumors remains unclear, and the prevalence of pathogenic germline variants in patients ...
    • The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms 

      Venizelos, Andreas; Elvebakken, Hege; Perren, Aurel; Nikolaienko, Oleksii; Deng, Wei; Lothe, Inger Marie Bowitz; Couvelard, Anne; Hjortland, Geir Olav; Sundlöv, Anna; Svensson, Johanna; Garresori, Herish; Kersten, Christian; Hofsli, Eva; Detlefsen, Sönke; Krogh, Merete; Sørbye, Halfdan; Knappskog, Stian (Journal article; Peer reviewed, 2021)
      High-grade (HG) gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) are rare but have a very poor prognosis and represent a severely understudied class of tumours. Molecular data for HG GEP-NEN are limited, and ...
    • Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: A multicenter cohort study 

      Carlsen, Esben Andreas; Fazio, Nicola; Granberg, Dan; Grozinsky-Glasberg, Simona; Ahmadzadehfar, Hojjat; Grana, Chiara Maria; Zandee, Wouter T.; Cwikla, Jaroslaw; Walter, Martin A.; Oturai, Peter Sandor; Rinke, Anja; Weaver, Andrew; Frilling, Andrea; Gritti, Sara; Arveschoug, Anne Kirstine; Meirovitz, Amichay; Knigge, Ulrich; Sorbye, Halfdan (Peer reviewed; Journal article, 2019)
      Peptide receptor radionuclide therapy (PRRT) is an established treatment of metastatic neuroendocrine tumors grade 1–2 (G1–G2). However, its possible benefit in high-grade gastroenteropancreatic (GEP) neuroendocrine neoplasms ...